Sign in to view content

Baseline Characteristics of Patients Maintaining q12 and q16 Dosing With Aflibercept 8 mg vs Patients With Shortened Treatment Intervals Phase 3 PULSAR Post Hoc Analysis

David R. Chow, MD, FRCS(C)

Video
Published 2023

Related

Episode 9: Rate of Macular Atrophy in HARBOR Study with Dr. SriniVas Sadda
Keyvan Koushan, MD, FRCSC
Member Podcasts
2018
Clinical Effects of Blocking Ang-2 and VEGF with Faricimab in the Phase 2 STAIRWAY Trial
Carl J Danzig, MD
Annual Meeting Talks
2020
TIE2, VEGF, and Integrin Receptor Interplay and its Role in Retinal Disease
Peter K. Kaiser, MD FASRS
Updates from the Field
2020

Category: AMD-Neovascular

See more